JP2008526991A - ベンダムスチン製薬学的組成物 - Google Patents

ベンダムスチン製薬学的組成物 Download PDF

Info

Publication number
JP2008526991A
JP2008526991A JP2007551416A JP2007551416A JP2008526991A JP 2008526991 A JP2008526991 A JP 2008526991A JP 2007551416 A JP2007551416 A JP 2007551416A JP 2007551416 A JP2007551416 A JP 2007551416A JP 2008526991 A JP2008526991 A JP 2008526991A
Authority
JP
Japan
Prior art keywords
bendamustine
concentration
formulation
hours
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007551416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526991A5 (cg-RX-API-DMAC7.html
Inventor
ブリテイン,ジエイソン・エドワード
フランクリン,ジヨー・クレイグ
Original Assignee
セフアロン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008526991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セフアロン・インコーポレーテツド filed Critical セフアロン・インコーポレーテツド
Publication of JP2008526991A publication Critical patent/JP2008526991A/ja
Publication of JP2008526991A5 publication Critical patent/JP2008526991A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007551416A 2005-01-14 2006-01-13 ベンダムスチン製薬学的組成物 Pending JP2008526991A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64435405P 2005-01-14 2005-01-14
US11/330,868 US8436190B2 (en) 2005-01-14 2006-01-12 Bendamustine pharmaceutical compositions
PCT/US2006/001308 WO2006076620A2 (en) 2005-01-14 2006-01-13 Bendamustine pharmaceutical compositions for lyophilisation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012231760A Division JP5688195B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物
JP2012231759A Division JP5726833B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物

Publications (2)

Publication Number Publication Date
JP2008526991A true JP2008526991A (ja) 2008-07-24
JP2008526991A5 JP2008526991A5 (cg-RX-API-DMAC7.html) 2009-10-15

Family

ID=36678237

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007551416A Pending JP2008526991A (ja) 2005-01-14 2006-01-13 ベンダムスチン製薬学的組成物
JP2012231759A Expired - Lifetime JP5726833B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物
JP2012231760A Expired - Lifetime JP5688195B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012231759A Expired - Lifetime JP5726833B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物
JP2012231760A Expired - Lifetime JP5688195B2 (ja) 2005-01-14 2012-10-19 ベンダムスチン製薬学的組成物

Country Status (19)

Country Link
US (9) US8436190B2 (cg-RX-API-DMAC7.html)
EP (2) EP2574334A1 (cg-RX-API-DMAC7.html)
JP (3) JP2008526991A (cg-RX-API-DMAC7.html)
KR (4) KR20160098530A (cg-RX-API-DMAC7.html)
CN (1) CN102078305B (cg-RX-API-DMAC7.html)
AR (1) AR052877A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006204817B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0606332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2593582A1 (cg-RX-API-DMAC7.html)
EA (1) EA013324B1 (cg-RX-API-DMAC7.html)
ES (1) ES2405611T3 (cg-RX-API-DMAC7.html)
IL (1) IL184394A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007008562A (cg-RX-API-DMAC7.html)
MY (1) MY157661A (cg-RX-API-DMAC7.html)
NO (1) NO343659B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ556435A (cg-RX-API-DMAC7.html)
SG (1) SG158870A1 (cg-RX-API-DMAC7.html)
TW (1) TWI380830B (cg-RX-API-DMAC7.html)
WO (1) WO2006076620A2 (cg-RX-API-DMAC7.html)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110102392A (ko) * 2008-12-03 2011-09-16 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 고체 투약 형태
JP2012503666A (ja) * 2008-09-25 2012-02-09 セファロン、インク. ベンダムスチン液体製剤
JP2012519657A (ja) * 2009-02-25 2012-08-30 スプラテック ファーマ インコーポレイテッド ベンダムスチン環状多糖組成物
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク. ベンダムスチンの経口製剤
JP2013518130A (ja) * 2010-01-28 2013-05-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
WO2014208354A1 (ja) * 2013-06-25 2014-12-31 Takeuchi Tsutomu 炎症性疾患を治療又は予防するための医薬組成物
JP2015536996A (ja) * 2012-11-12 2015-12-24 イグニタ、インク. ベンダムスチン誘導体およびこれを使用する方法
US9572887B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9579384B2 (en) 2012-03-20 2017-02-28 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
JP2017507958A (ja) * 2014-03-13 2017-03-23 ブードーリス,バシリオス ベンダムスチン固体分散体及び持続注入
JP2017533950A (ja) * 2014-11-14 2017-11-16 ナビンタ トゥー エルエルシー カルムスチン医薬組成物

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US20090082416A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
EP2583670A1 (en) * 2007-10-09 2013-04-24 US Worldmeds LLC Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
AR072777A1 (es) * 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2010056733A1 (en) * 2008-11-13 2010-05-20 Indiana University Research And Technology Corporation Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
KR20110110293A (ko) * 2009-01-15 2011-10-06 세파론, 인코포레이티드 벤다무스틴 유리 염기의 신규 형태
ME02254B (me) 2009-01-23 2015-12-31 Euro Celtique Sa Derivati hidroksamske kiseline
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
US20110015245A1 (en) * 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) * 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
AU2011260615B2 (en) 2010-06-02 2016-11-17 Pharma& Schweiz Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
WO2012009299A1 (en) * 2010-07-13 2012-01-19 Cephalon, Inc. Improved methods for the sterilization of bendamustine
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
EP2667868A4 (en) * 2011-01-25 2014-12-10 Reddys Lab Ltd Dr Benda MUSTIN FORMULATIONS
CN107837395A (zh) * 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
UA110853C2 (uk) * 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
ES2613838T3 (es) 2011-09-26 2017-05-26 Fresenius Kabi Oncology Ltd Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina
WO2013102920A1 (en) 2011-11-18 2013-07-11 Astron Research Limited Stable lyophilized formulation of bendamustine
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
TWI573792B (zh) * 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
IN2012DE00337A (cg-RX-API-DMAC7.html) 2012-02-06 2015-04-10 Fresenius Kabi Oncology Ltd
CA2864118A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2013148919A1 (en) 2012-03-30 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment of multiple myeloma
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
ES2564274T3 (es) 2012-11-19 2016-03-21 Oncotec Pharma Produktion Gmbh Procedimiento para la preparación de una composición liofilizada
CN103860482B (zh) * 2012-12-12 2016-08-24 海口市制药厂有限公司 一种盐酸苯达莫司汀冻干粉针剂的制备方法、其产品及用途
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
WO2014127802A1 (en) 2013-02-19 2014-08-28 Synthon Bv Stable compositions of bendamustine
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
ITMI20131013A1 (it) * 2013-06-19 2014-12-20 Chemi Spa Formulazioni liofilizzate di bendamustina cloridrato
CN103351347A (zh) * 2013-07-29 2013-10-16 东南大学 盐酸苯达莫司汀杂质dce的制备方法
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
US20150087681A1 (en) * 2013-09-25 2015-03-26 Pranav Patel Bendamustine HCL Stable Lyophilized Formulations
WO2015054550A1 (en) * 2013-10-11 2015-04-16 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
IN2014CH00151A (cg-RX-API-DMAC7.html) * 2014-01-13 2015-07-17 Hetero Research Foundation
US20150320774A1 (en) 2014-05-09 2015-11-12 AuroMedics Pharma LLC Formulations of cyclophosphamide liquid concentrate
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
US20170119794A1 (en) * 2015-11-04 2017-05-04 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
EP3836921B1 (en) 2018-08-17 2025-10-08 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
US11406598B2 (en) 2019-09-20 2022-08-09 Nivagen Pharmaceuticals, Inc. Lyophilized compositions of phenobarbital sodium salt
CN110638765A (zh) * 2019-11-08 2020-01-03 江苏食品药品职业技术学院 一种卡莫司汀冻干工艺
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DE80967C (cg-RX-API-DMAC7.html)
DE1354952U (cg-RX-API-DMAC7.html)
DD80967A (cg-RX-API-DMAC7.html)
DE159289C (cg-RX-API-DMAC7.html) 1903-10-08 1905-03-16
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159877A1 (de) 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
ES2040394T3 (es) 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5741523A (en) 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5561121A (en) * 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
EP0804434A1 (en) * 1994-08-02 1997-11-05 MERCK SHARP & DOHME LTD. Azetidine, pyrrolidine and piperidine derivatives
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
JPH11511463A (ja) 1995-08-31 1999-10-05 スミスクライン・ビーチャム・コーポレイション インターロイキン変換酵素およびアポプトーシス
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
JP2002520282A (ja) 1998-07-09 2002-07-09 フランシス エイ. ナーデラ, 慢性リンパ性白血病の処置のための方法および組成物
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR20040025881A (ko) 2000-12-11 2004-03-26 다케다 야쿠힌 고교 가부시키가이샤 개선된 흡수성을 갖는 의약 조성물
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
DK1435877T3 (da) * 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
AU2003221517B2 (en) 2002-03-22 2010-02-18 Christian Straka Cytocapacity test
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1501565B1 (de) 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen
US20040096436A1 (en) 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
NZ540318A (en) 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1594900A2 (en) 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 cci- 779 제형
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503666A (ja) * 2008-09-25 2012-02-09 セファロン、インク. ベンダムスチン液体製剤
JP2017057225A (ja) * 2008-12-03 2017-03-23 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの固体投与剤
JP2012510483A (ja) * 2008-12-03 2012-05-10 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの固体投与剤
KR101710935B1 (ko) 2008-12-03 2017-02-28 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 고체 투약 형태
KR20110102392A (ko) * 2008-12-03 2011-09-16 아스텔라스 도이칠란트 게엠베하 벤다무스틴의 고체 투약 형태
JP2015061864A (ja) * 2008-12-03 2015-04-02 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテルハフツング ベンダムスチンの固体投与剤
JP2012519657A (ja) * 2009-02-25 2012-08-30 スプラテック ファーマ インコーポレイテッド ベンダムスチン環状多糖組成物
JP2012525387A (ja) * 2009-04-28 2012-10-22 セファロン、インク. ベンダムスチンの経口製剤
US11872214B2 (en) 2010-01-28 2024-01-16 Eagle Pharmaceuticals, Inc. Formulations of Bendamustine
JP2016020365A (ja) * 2010-01-28 2016-02-04 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11103483B2 (en) 2010-01-28 2021-08-31 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572797B2 (en) 2010-01-28 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572796B2 (en) 2010-01-28 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US12350257B2 (en) 2010-01-28 2025-07-08 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP2013518130A (ja) * 2010-01-28 2013-05-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
US10010533B2 (en) 2010-01-28 2018-07-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9579384B2 (en) 2012-03-20 2017-02-28 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US9597397B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9597398B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9597399B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US10052385B2 (en) 2012-03-20 2018-08-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572888B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572887B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP2015536996A (ja) * 2012-11-12 2015-12-24 イグニタ、インク. ベンダムスチン誘導体およびこれを使用する方法
WO2014208354A1 (ja) * 2013-06-25 2014-12-31 Takeuchi Tsutomu 炎症性疾患を治療又は予防するための医薬組成物
JP2017507958A (ja) * 2014-03-13 2017-03-23 ブードーリス,バシリオス ベンダムスチン固体分散体及び持続注入
JP2017533950A (ja) * 2014-11-14 2017-11-16 ナビンタ トゥー エルエルシー カルムスチン医薬組成物

Also Published As

Publication number Publication date
US20140148490A1 (en) 2014-05-29
US20130041003A1 (en) 2013-02-14
KR101918188B1 (ko) 2018-11-14
NZ556435A (en) 2011-01-28
US20200237726A1 (en) 2020-07-30
US8436190B2 (en) 2013-05-07
BRPI0606332A2 (pt) 2009-11-17
CA2593582A1 (en) 2006-07-20
JP2013056901A (ja) 2013-03-28
US8609863B2 (en) 2013-12-17
NO20073722L (no) 2007-09-27
TW200637614A (en) 2006-11-01
US8461350B2 (en) 2013-06-11
HK1116073A1 (en) 2008-12-19
ES2405611T3 (es) 2013-05-31
US20180296534A1 (en) 2018-10-18
JP5688195B2 (ja) 2015-03-25
US20130131131A1 (en) 2013-05-23
IL184394A0 (en) 2007-10-31
MY157661A (en) 2016-07-15
US20060159713A1 (en) 2006-07-20
KR20170096221A (ko) 2017-08-23
US20130123316A1 (en) 2013-05-16
WO2006076620A3 (en) 2006-12-28
EP1863452A2 (en) 2007-12-12
EP2574334A1 (en) 2013-04-03
KR20160098530A (ko) 2016-08-18
NO343659B1 (no) 2019-04-29
KR101648495B1 (ko) 2016-08-17
WO2006076620A2 (en) 2006-07-20
US20150374671A1 (en) 2015-12-31
CN102078305A (zh) 2011-06-01
AU2006204817A1 (en) 2006-07-20
KR20180056804A (ko) 2018-05-29
TWI380830B (zh) 2013-01-01
EP1863452B1 (en) 2013-04-03
US20130338205A1 (en) 2013-12-19
MX2007008562A (es) 2007-09-07
AU2006204817B2 (en) 2010-11-25
EA200701511A1 (ru) 2007-12-28
AR052877A1 (es) 2007-04-11
US8895756B2 (en) 2014-11-25
US8791270B2 (en) 2014-07-29
CN102078305B (zh) 2014-05-28
EA013324B1 (ru) 2010-04-30
SG158870A1 (en) 2010-02-26
JP5726833B2 (ja) 2015-06-03
JP2013056902A (ja) 2013-03-28
KR20070094848A (ko) 2007-09-21

Similar Documents

Publication Publication Date Title
JP5688195B2 (ja) ベンダムスチン製薬学的組成物
US20240299363A1 (en) Bendamustine pharmaceutical compositions
CN101119708B (zh) 苯达莫司汀冻干药物组合物
HK1116073B (en) Bendamustine pharmaceutical compositions for lyophilisation
HK1182009A (en) Bendamustine pharmaceutical compositions for lyophilisation

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090113

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120619